10 Most Profitable Healthcare Stocks to Buy

7. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Net Income (TTM): $4.58 billion

Operating Margin (TTM): 29.56%

Number of Hedge Fund holdings: 78

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported Q4 2025 results on January 30, with revenue coming in at $3.9 billion (+3.0% year over year), which were around 3% ahead of consensus. Profitability was even better with adjusted EPS for the quarter reaching $11.44, 7% above street expectations.

Focusing on the drivers of healthy performance, the company’s President and CEO, Leonard S. Schleifer, stated,

Regeneron performed well in 2025, with financial strength driven by our four blockbuster medicines and future growth supported by our exciting late-stage clinical portfolio. In the fourth quarter, we secured label expansions and new filler solutions for EYLEA HD, further enhancing its commercial potential. Dupixent received new approvals in Japan and Europe and is currently the most widely used innovative branded antibody medicine, with over 1.4 million active patients worldwide. Libtayo also secured additional approvals and continues to be the leading immunotherapy for non-melanoma skin cancers.

Around four days before the results were released, BofA Securities maintained its Buy rating and $860 price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). The firm fully incorporates the impact of the company’s 2026 R&D estimates, $60 million donation, fourth quarter Eylea pre-announcement, and IPR&D disclosure.

BofA Securities expected Q4 Sanofi collaboration revenues of $1.6 billion, up 32% YoY, Bayer collaboration revenues of $361 million, down 4% YoY, and Libtayo revenues of $425 million, up 16% YoY. For 2026, the firm estimated U.S. Eylea franchise revenues of $4.43 billion, which is higher than both its initial forecast of $4.35 billion and the consensus projection of $3.95 billion. Thus, the reaffirmed buy rating was driven by several factors, including Eylea HD prospects, Dupixent upside potential, and the company’s pipeline opportunities.

Earlier, on January 22, Evercore ISI lifted the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $875 from $750 and reiterated an Outperform rating. The firm highlighted Dupixent’s sustained growth momentum and the upcoming Eylea HD, which is expected to compete fiercely with a prefilled syringe launch scheduled for the second quarter of 2026.

​Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a leading biotechnology company serving people with eye, cardiovascular, cancer, and inflammatory diseases. Headquartered in New York, the company develops and markets life-changing medicines for people with severe illnesses.